Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-remitting Multiple Sclerosis”

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT01578785
What this trial is testing

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 178
Testing effectiveness (Phase 2)Ended earlyNCT00219908
What this trial is testing

Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Rennes University Hospital 124
Early research (Phase 1)Ended earlyNCT03594487
What this trial is testing

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Jeffrey Gelfand 5
Not applicableStudy completedNCT02258217
What this trial is testing

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
OhioHealth 30
Post-approval studies (Phase 4)Study completedNCT00078338
What this trial is testing

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
EMD Serono 764
Large-scale testing (Phase 3)Ended earlyNCT03368664
What this trial is testing

Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Who this might be right for
Multiple Sclerosis
Genzyme, a Sanofi Company 16
Large-scale testing (Phase 3)Study completedNCT00428584
What this trial is testing

RNF and Betaseron® Tolerability Study

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
EMD Serono 129
Not applicableStudy completedNCT00492570
What this trial is testing

GER-009-06-AVX Early Therapy in Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 230
Testing effectiveness (Phase 2)UnknownNCT00917839
What this trial is testing

The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Cantonal Hospital of St. Gallen 88
Not applicableStudy completedNCT02823951
What this trial is testing

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Who this might be right for
Relapsing-remitting Multiple Sclerosis
IMS HEALTH GmbH & Co. OHG 479
Not applicableStudy completedNCT01110993
What this trial is testing

An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 65
Not applicableStudy completedNCT04220814
What this trial is testing

Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Rennes University Hospital 94
Testing effectiveness (Phase 2)Looking for participantsNCT07510607
What this trial is testing

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

Who this might be right for
Multiple SclerosisRRMSRelapsing Remitting MS
Ari Green 40
Post-approval studies (Phase 4)Ended earlyNCT02342704
What this trial is testing

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 111
Testing effectiveness (Phase 2)Study completedNCT00235989
What this trial is testing

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bayer 63
Large-scale testing (Phase 3)Not Yet RecruitingNCT07503340
What this trial is testing

Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Hoffmann-La Roche 25
Not applicableLooking for participantsNCT07736482
What this trial is testing

Relationship Between Single- and Dual-Task Obstacle Crossing Performance and Fatigue and Disability in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Afyonkarahisar Health Sciences University 30
Not applicableNot Yet RecruitingNCT07762040
What this trial is testing

Predictors of Progression Independent of Relapse Activity in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Assiut University 180
Testing effectiveness (Phase 2)Study completedNCT00097188
What this trial is testing

Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Genentech, Inc. 104
Testing effectiveness (Phase 2)Study completedNCT00587691
What this trial is testing

Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Opexa Therapeutics, Inc. 16
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation